Publicacións nas que colabora con Pedro Pérez Segura (15)

2024

  1. T-reg transcriptomic signatures identify response to check-point inhibitors

    Scientific Reports, Vol. 14, Núm. 1

2022

  1. Genomic mapping of copy number variations influencing immune response in breast cancer

    Frontiers in Oncology, Vol. 12

  2. Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates

    Frontiers in Immunology, Vol. 12

2021

  1. Genomic correlates of dna damage in breast cancer subtypes

    Cancers, Vol. 13, Núm. 9

  2. Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer

    Cancers, Vol. 13, Núm. 16

  3. In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer

    Cellular Oncology, Vol. 44, Núm. 3, pp. 569-580

  4. Mapping of genomic vulnerabilities in the post-translational ubiquitination, sumoylation and neddylation machinery in breast cancer

    Cancers, Vol. 13, Núm. 4, pp. 1-23

  5. Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer

    Frontiers in Oncology, Vol. 11

2020

  1. Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine

    Frontiers in Oncology, Vol. 10

  2. Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

    Frontiers in Oncology, Vol. 9

  3. Genomic mapping identifies mutations in ryr2 and ahnak as associated with favorable outcome in basal-like breast tumors expressing pd1/pd-l1

    Cancers, Vol. 12, Núm. 8, pp. 1-15

  4. Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis

    Molecular Diagnosis and Therapy, Vol. 24, Núm. 2, pp. 143-151

2019

  1. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

    Frontiers in Immunology, Vol. 10

  2. Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis

    Frontiers in Oncology, Vol. 9

  3. Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis

    Cancer Treatment Reviews, Vol. 77, pp. 11-19